• Researchers looked at current, ineffective models of HFpEF and concluded that none of them correctly mirrors the realities they see clinically in human patients
• They found that combining a high-fat diet with a drug that raises BP gave them a “two-hit” model, like a one-two punch to the disease

Nearly half of current hospital admissions for heart failure are caused by a type of the disease with no treatment options. Cardiology researchers at UT Southwestern Medical Center are changing that reality with a fresh approach, recently published in Nature.

“There are two types of heart failure. One is called [heart failure with reduced ejection fraction] HFrEF, for which we have a number of therapies, including medications, devices, and transplants. The other—[heart failure with preserved ejection fraction] HFpEF—has zero options,” explained UT Southwestern chief of the Division of Cardiology and professor of internal medicine and molecular biology Dr. Joseph Hill.

“HFpEF is the single greatest unmet need in cardiology. Finding a new way to examine it represents a significant advance, as it provides a model necessary to develop and test therapies that could save lives worldwide,” said Dr. Hill, who holds the James T. Willerson, MD, distinguished chair in cardiovascular diseases and the Frank M. Ryburn, Jr. chair in heart research.

The Centers for Disease Control and Prevention estimates that 5.7 million people have heart failure in the United States. HFpEF is a lethal disorder for which there are no effective clinical therapies. The heart muscle becomes too stiff to pump blood efficiently. Most HFpEF patients are obese, have diabetes, and have metabolic syndrome.

HFrEF functions differently. In HFrEF, also known as systolic HF, the heart muscle is not able to contract adequately and, therefore, expels less oxygen-rich blood into the body.

Previous heart failure models of HFpEF focused on raising the levels of an enzyme called NO, or nitric oxide synthase. However, in HFpEF, there is actually too much of the NO enzyme. A strike on this target—with a medical inhibitor, for example—would solve the problem. According to Dr. Hill, there are already US Food and Drug Administration (FDA)-approved drugs that inhibit this NO-synthesize enzyme, which could facilitate developing new treatments rapidly.

The two-hit model

Dr. Hill’s team looked at current, ineffective models of HFpEF and concluded that none of them correctly mirrors the realities they see clinically in human patients. They found that combining a high-fat diet with a drug that raises blood pressure gave them a “two-hit” model, like a one-two punch to the disease.

Next, the team examined results of their model at the cellular level and compared them with human cells. They found that they had replicated the human condition, thereby providing scientists an accurate biological picture that can greatly advance the development of new treatments.

“A recognized research gap in the HFpEF field is the lack of relevant experimental models that adequately represent the progression of this complex disorder. This study is an example of how advances in HFpEF models can lead to a better understanding of the disease pathophysiology and new ideas for therapeutic strategies,” said Dr. Bishow Adhikari, a program officer for the study and a scientist with the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, which helped fund the study.

Millions of people worldwide have both obesity and diabetes. The research team believed that these two conditions would lead to HFpEF—a hypothesis they confirmed by duplicating the disease conditions and examining changes at the molecular level.

“Heart failure is one of only two forms of cardiovascular disease that is increasing. It’s exploding around the world,” Dr. Hill said. “We dance around the edges of it, treating patients’ diabetes, blood pressure, and other conditions. With this model, we’ll be able to get to the underlying cause so we can get to the root of the problem.”

The UT Southwestern researchers are currently taking steps toward moving into human clinical trials based on findings in their preclinical two-hit model. With time, they expect that all heart failure patients will have treatment options.

Dr. Hill is director of the Harry S. Moss Heart Center and editor-in-chief of Circulation.